Friday, 25 March 2016 16:08

Anticoagulation news items. Weeks commencing 21st March 2016

Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study

The Lancet Haematology

Analysis suggests extended treatment with edoxaban (ED) is as effective as warfarin (WF) [incidence recurrent venous thromboembolism between 3 and 12 months = 0·3% (11 of 3633) with ED and 0.4% (14 of 3594) with WF; HR 0.78, 95% CI 0.36–1.72] and linked to less major bleeding.


Astra Zeneza announces that ticagrelor fails to meet primary efficacy endpoint in SOCRATES trial


The drug failed on the primary efficacy endpoint of increasing the time to first occurrence of stroke (ischaemic or haemorrhagic), myocardial infarction or death vs aspirin in patients who have experienced an acute ischaemic stroke or transient ischaemic attack.


Positive results in first six months for anticoagulant hospital referral service

Pharmaceutical Services Negotiating Committee

Since launch (6 months) 138 patients have been referred to Swindon and Wiltshire Local Pharmaceutical Committee anticoagulant referral service with Great Western Hospital. This report highlights the positive outcomes experienced.



The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be
found at: